Immunotherapy with checkpoint inhibitors has changed the paradigm of treatment for many
tumors, and endometrial carcinoma is not an exception. Approved treatment options are …

Background When determining adjuvant treatment for endometrial cancer, the decision
typically relies on factors such as cancer stage, histologic grade, subtype, and a few …

Recent studies suggest that B cells could play an important role in the tumor
microenvironment. However, the role of humoral responses in endometrial cancer remains …

Endometrial cancer (EC) can easily be cured when diagnosed at an early stage. However,
advanced and metastatic EC is a common disease, affecting more than 15,000 patients per …

Since endometrial cancers (ECs) are frequently TMB-H and MSI-H/dMMR tumors, this
element has provided the rationale for testing immune checkpoint inhibitors (ICIs), which …

Mismatch repair-deficient (dMMR) tumors show a good response toward immune checkpoint
inhibitors (ICI), but develo** resistance impairs patients' outcomes. Here, we compared …

Backgrounds Uterine corpus endometrial carcinoma (UCEC) is one of the greatest threats
on the female reproductive system. The aim of this study is to explore the inflammation …

Endometrial cancer is rising in prevalence. The standard treatment modality of hysterectomy
is becoming increasingly inadequate due primarily to the direct link between endometrial …

To explore the potential function of methyltransferase-like 5 (METTL5) in uterine corpus
endometrial carcinoma (UCEC) and verify the relationship between deficient DNA mismatch …

Background Endometrial cancer (EC) is a common gynecological cancer worldwide and the
sixth most common female malignant tumor. A large number of studies conducted through …